Sign up
Pharma Capital

Soleno stock price triples as safety board gives go-ahead to continue Prader-Willi trial

The Data Safety Monitoring Board has recommended that the trial known as DESTINY PWS continue without changes
Scientist with test tubes
The company said it was continuing to enroll patients

Soleno Therapeutics Inc (NASDAQ:SLNOW) tripled in Friday's Nasdaq trading as the biopharma company received good news about its Phase 3 trial on a tablet for Prader-Willi syndrome (PWS).

The Data Safety Monitoring Board (DSMB) has recommended that the trial known as DESTINY PWS for the diazoxide choline controlled-release tablet continue without any changes. 

Shares in Soleno surged 223% on the Nasdaq index to $4.36.

READ: Soleno Therapeutics shares surge on positive patent news

The hallmark symptom of PWS is hyperphagia, a chronic feeling of insatiable hunger. Patients can also suffer from behavioral problems, cognitive disabilities, low muscle tone, excess body fat and incomplete sexual development.

“We are delighted with the DSMB’s positive recommendation to continue the Phase 3 trial as planned as it further supports DCCR’s safety profile,” Dr Anish Bhatnagar, CEO at Soleno, said in a statement. "We are continuing to enrol patients with 14 sites activated in DESTINY PWS."

He added that patients continue to roll over into C602, the nine-month, open-label safety extension study for patients completing treatment in the DESTINY PWS study. 

The DESTINY PWS trial is a randomized, double-blind, placebo-controlled study of once-daily oral administration of DCCR in about 100 patients with a confirmed diagnosis of PWS.

Diazoxide choline has received orphan drug designation for the treatment of PWS in the US and EU.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

Giles_55af4ddca6481.jpg


Register here to be notified of future SLNOW Company articles
View full SLNOW profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.